No Benefit of Apolipoprotein A-I Infusions After Myocardial Infarction

CSL112, known to increase apoA-I levels and cholesterol efflux capacity, was no better than placebo in improving cardiovascular outcomes.

Cholesterol efflux (cholesterol removal from the artery wall) is thought to be the key mechanism by which high-density lipoprotein (HDL) affects atherosclerosis. Apolipoprotein A-I (apoA-I), the main protein portion of HDL, is the predominant mediator of cholesterol efflux. Patients with acute coronary syndromes have impaired cholesterol efflux, which is believed to result in poorer cardiovascular outcomes.

Might improving cholesterol efflux reduce risk for cardiovascular events? To find out, researchers enrolled 18,219 adults with myocardial infarction (MI) in the past 5 days, multivessel coronary artery disease, and additional cardiovascular risk factors in a manufacturer-funded, randomized, double-blind trial comparing 4 weekly infusions …

Reviewing Author

Karol E. Watson, MD, PhD, FACC

Disclosures

Consultant/Advisory BoardBoehringer Ingelheim; Amgen; Novartis; Lilly; Amarin

Speaker’s BureauBoehringer Ingelheim

Grant/Research SupportNIH

Editorial BoardsCirculation (Associate Editor)